Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)
|ClinicalTrials.gov Identifier: NCT01545778|
Recruitment Status : Completed
First Posted : March 7, 2012
Last Update Posted : October 29, 2012
|Condition or disease||Intervention/treatment|
|Substance Abuse Detection||Drug: Tapentadol IR Drug: Oxycodone IR|
|Study Type :||Observational|
|Actual Enrollment :||646620 participants|
|Official Title:||Risk of Shopping Behavior of Tapentadol IR Immediate-Release (IR) Compared to Oxycodone IR Immediate-Release (IR)|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||February 2012|
|Actual Study Completion Date :||February 2012|
Drug: Tapentadol IR
Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
Drug: Oxycodone IR
Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
- Proportion of patients who developed shopping behavior defined as patients with prescriptions with at least one day of overlap, written by ≥ 2 different prescribers and filled in 3 or more pharmacies [ Time Frame: 12 months ]
- Time to first episode of shopping behavior [ Time Frame: 12 months ]
- The number of shopping episodes during the year of follow up [ Time Frame: 12 months ]
- The type of dispensing in the first episode of shopping event [ Time Frame: 12 months ]The type of dispensing in the shopping event will be classified as "Only the indexed opioid" "Indexed opioid was involved", or "Indexed opioid was not involved at all".
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01545778
|Study Director:||Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|